REG - Aptamer Group PLC - Result of General Meeting

AptamerAnnouncement

Yesterday 13:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260413:nRSM2391Aa&default-theme=true

RNS Number : 2391A  Aptamer Group PLC  13 April 2026

 

13 April 2026

Aptamer Group plc

 

("Aptamer Group", "APTA" or the "Company")

 

Result of General Meeting

 

Aptamer Group (AIM: APTA), the leading developer of next-generation synthetic
binders delivering innovation to the life science industry, announces that,
further to the Company's announcements on 25 March 2026 and 26 March 2026, at
its General Meeting ("GM") held today, all Resolutions were passed.

 

Accordingly, all of the proposals set out in the Company's circular dated 27
March 2026 (the "Circular") will proceed.

 

In connection with the Fundraise, the Company has raised approximately £4.55
million through the issue of 758,165,573 new Ordinary Shares at the Issue
Price of 0.6p per share, comprising 230,083,333 Firm Placing Shares which were
admitted to trading on 31 March 2026 and 528,082,240 Conditional Shares
(comprising 306,583,333 Conditional Placing Shares, 175,833,334 Subscription
Shares and 45,665,573 Retail Offer Shares) which were conditional on the
Resolutions passed at the GM.  Accordingly, the Company has issued and
allotted the Conditional Shares and application has been made to the London
Stock Exchange for the Conditional Shares to be admitted to trading on AIM on
or around 8.00 am on 16 April 2026 ("Second Admission").

 

Total Voting Rights

Following Second Admission, the Company's enlarged issued ordinary share
capital will be 3,455,143,950 Ordinary Shares, with no shares held in
treasury. This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

Capitalised terms in this announcement have the same meaning as defined in the
Proposed Placing, Subscription and Retail Offer announcement made by the
Company on 25 March 2026.

 

The person responsible for the release of this announcement is Andrew Rapson,
Chief Financial Officer.

 

-      Ends -

 

For further information please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404

 Dr Arron Tolley, Chief Executive Officer

 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550

 Andrew Emmott / Dillon Wall

 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 Andrew Thacker / Guy McDougall

 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group plc

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go
to https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMAKNBKBBKDQQD



            Copyright 2019 Regulatory News Service, all rights reserved